Epalex
Palo Alto
About Epalex
EpaleX is developing a novel inhaled treatment for epilepsy and migraine. The treatment for the first time provides a way for patients with epilepsy to gain control over their seizures. When a seizure warning sign (aura) occurs, the patient will be able to prevent the development of a full-blown seizure through the use of a pocket nebulizer to deliver a powerful antiseizure medication that rapidly enters the brain and stops the seizure. The effect of the drug dissipates within minutes, allowing the patient to resume normal daily activity. The inhaler is also used to stop migraine attacks that are refractory to currently available migraine treatments.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $30.8M
- Last round: Series Unknown (Nov 2025)
- Website: epalex.com
- Phone: (650) 346-3380
Industries & Categories
Biotechnology, Health Care, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/epalex-12825 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.